<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448068</url>
  </required_header>
  <id_info>
    <org_study_id>17-000301</org_study_id>
    <nct_id>NCT03448068</nct_id>
  </id_info>
  <brief_title>Perioperative Ketamine for Pain With Gastric Bypass</brief_title>
  <official_title>Low-dose Ketamine Infusions for Perioperative Pain Management in Patients Undergoing Laparoscopic Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid medications such as morphine, hydrocodone and oxycodone are standard for treating pain&#xD;
      after surgery, however there are disadvantages. Because of the way opioids work, gastric&#xD;
      bypass patients may have an increased risk of having sedation or problems with breathing. In&#xD;
      patients with sleep apnea, opioids may increase the risk of severe apnea.&#xD;
&#xD;
      Ketamine is an alternative pain medicine that can be used to treat pain after surgery and may&#xD;
      have fewer effects on breathing. Using ketamine as part of the regimen may be a better choice&#xD;
      for laparoscopic gastric bypass patients.&#xD;
&#xD;
      This study is being done to find out if intraoperative ketamine infusion combined with&#xD;
      continuation for twenty-four hours post-surgery provides superior pain control and decreases&#xD;
      post-operative opioid use versus standard non-ketamine therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">January 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Cumulative Perioperative Opioid Dose</measure>
    <time_frame>approximately 48 hours after induction of anesthesia</time_frame>
    <description>Measured in oral morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Pain Score 0-12 Hours</measure>
    <time_frame>approximately 0-12 hours post operatively</time_frame>
    <description>Patient reported pain scores at 0-12 hours post operatively. Measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain. A higher score indicates great pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Pain Score 12-24 Hours</measure>
    <time_frame>approximately 12-24 hours post operatively</time_frame>
    <description>Patient reported pain scores at 12-24 hours post operatively. Measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain. A higher score indicates great pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Pain Score 24-48 Hours</measure>
    <time_frame>approximately 24-48 hours post operatively</time_frame>
    <description>Patient reported pain scores at 24-48 hours post operatively. Measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain. A higher score indicates great pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Operative Nausea</measure>
    <time_frame>12 hours, 24 hours, and 48 hours</time_frame>
    <description>Number of subject to experience post-operative nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in Hospital</measure>
    <time_frame>Arrival at hospital until discharge from hospital, approximately 2 days</time_frame>
    <description>Length of hospital stay measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Pain Control at Time of Hospital Discharge</measure>
    <time_frame>approximately 1-2 days post-operatively</time_frame>
    <description>Self-reported questionnaire at the time of discharge from the hospital rating satisfaction of pain treatment while in the hospital using a scale of 0= extremely dissatisfied, 10 = extremely satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Pain Control at Postoperative Visit</measure>
    <time_frame>approximately 30 days post-operatively</time_frame>
    <description>Self-reported questionnaire at the time of first post-operative visit with the surgeon, rating the worst amount of pain since being discharged from the hospital using a scale of 0= no pain, 10 = worst pain possible.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Laparoscopic Gastric Bypass Surgery</condition>
  <condition>Ketamine</condition>
  <arm_group>
    <arm_group_label>Ketamine Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine 0.3 mg/kg (IBW) bolus with induction.&#xD;
Ketamine infusion 0.2 mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.&#xD;
Ketamine infusion will not be titrated.&#xD;
Remaining care will be identical to standard therapy group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calculation ideal body weight (IBW)&#xD;
Pre-op dexamethasone&#xD;
Pre-op midazolam at discretion of anesthesiologist&#xD;
Anesthesia Induction - Propofol and fentanyl, anesthesiologist discretion. Neuromuscular block with succinylcholine and/or rocuronium at discretion of anesthesiologist. Orotracheal intubation.&#xD;
Anesthesia Maintenance - Sevoflurane/rocuronium. Addl. doses of fentanyl, discretion of anesthesiologist.&#xD;
Emergence from anesthesia - Acetaminophen, Ketorolac and Ondansetron unless contraindicated. Sugammadex depending on twitch response per drug manufacturer recommended protocol.&#xD;
Post-Op Analgesia - Hydromorphone, acetaminophen and ketorolac&#xD;
Other post-op care as per usual surgical routine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.&#xD;
Ketamine infusion not titrated.</description>
    <arm_group_label>Ketamine Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard therapy</intervention_name>
    <description>Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.&#xD;
Other standard surgical post-op care</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing laparoscopic gastric bypass at Mayo Clinic in Arizona&#xD;
&#xD;
          2. BMI is â‰¥ 35 kg/m2&#xD;
&#xD;
          3. Consent is able to be obtained as per Mayo Clinic policy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intolerance to ketamine&#xD;
&#xD;
          2. History of schizophrenia, schizoaffective disorder, or other psychiatric diagnosis&#xD;
             with psychotic features&#xD;
&#xD;
          3. Presence of unstable cardiovascular disease (presence of acute coronary syndrome,&#xD;
             unstable angina, hypertension emergency, acute transient ischemic attack (TIA) or&#xD;
             stroke)&#xD;
&#xD;
          4. Presence of acute elevation of intracranial or intraocular pressure&#xD;
&#xD;
          5. Presence of seizure disorder&#xD;
&#xD;
          6. History of substance abuse or addiction&#xD;
&#xD;
          7. Creatinine greater than 1.5 mg/dL&#xD;
&#xD;
          8. End-stage liver disease&#xD;
&#xD;
          9. Pregnancy&#xD;
&#xD;
         10. Patients with chronic pain and/or chronic opioid therapy will not be excluded to more&#xD;
             closely replicate the study patient population of interest. However, patients taking&#xD;
             greater than 50 morphine equivalents (ME) per day for greater than 1 month prior to&#xD;
             surgery will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew W Gorlin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <results_first_submitted>March 8, 2021</results_first_submitted>
  <results_first_submitted_qc>April 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 29, 2021</results_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Andrew Gorlin, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology, College of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03448068/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine Therapy</title>
          <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
        </group>
        <group group_id="P2">
          <title>Standard Therapy</title>
          <description>Subjects received standard of care anesthesia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine Therapy</title>
          <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
        </group>
        <group group_id="B2">
          <title>Standard Therapy</title>
          <description>Subjects received standard of care anesthesia</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="11.5"/>
                    <measurement group_id="B2" value="48.8" spread="10.2"/>
                    <measurement group_id="B3" value="51.5" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Cumulative Perioperative Opioid Dose</title>
        <description>Measured in oral morphine equivalents</description>
        <time_frame>approximately 48 hours after induction of anesthesia</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Therapy</title>
            <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Subjects received standard of care anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cumulative Perioperative Opioid Dose</title>
          <description>Measured in oral morphine equivalents</description>
          <units>Morphine Equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.9" spread="113.1"/>
                    <measurement group_id="O2" value="248.6" spread="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Pain Score 0-12 Hours</title>
        <description>Patient reported pain scores at 0-12 hours post operatively. Measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain. A higher score indicates great pain intensity.</description>
        <time_frame>approximately 0-12 hours post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Therapy</title>
            <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Subjects received standard of care anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Score 0-12 Hours</title>
          <description>Patient reported pain scores at 0-12 hours post operatively. Measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain. A higher score indicates great pain intensity.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.2"/>
                    <measurement group_id="O2" value="4.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2252</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Pain Score 12-24 Hours</title>
        <description>Patient reported pain scores at 12-24 hours post operatively. Measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain. A higher score indicates great pain intensity.</description>
        <time_frame>approximately 12-24 hours post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Therapy</title>
            <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Subjects received standard of care anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Score 12-24 Hours</title>
          <description>Patient reported pain scores at 12-24 hours post operatively. Measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain. A higher score indicates great pain intensity.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.9"/>
                    <measurement group_id="O2" value="3.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0610</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Pain Score 24-48 Hours</title>
        <description>Patient reported pain scores at 24-48 hours post operatively. Measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain. A higher score indicates great pain intensity.</description>
        <time_frame>approximately 24-48 hours post operatively</time_frame>
        <population>2 subjects were discharged early so data was not collected or analyzed for 1 subject from the ketamine therapy group and 1 subject from the standard therapy group</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Therapy</title>
            <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Subjects received standard of care anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Score 24-48 Hours</title>
          <description>Patient reported pain scores at 24-48 hours post operatively. Measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain. A higher score indicates great pain intensity.</description>
          <population>2 subjects were discharged early so data was not collected or analyzed for 1 subject from the ketamine therapy group and 1 subject from the standard therapy group</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.9"/>
                    <measurement group_id="O2" value="3.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2720</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Operative Nausea</title>
        <description>Number of subject to experience post-operative nausea</description>
        <time_frame>12 hours, 24 hours, and 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Therapy</title>
            <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Subjects received standard of care anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Operative Nausea</title>
          <description>Number of subject to experience post-operative nausea</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea 1st 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea 2nd 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea 2nd 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nausea 1st 12 hours for Ketamine Therapy vs Standard Therapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7298</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nausea 2nd 12 hours for Ketamine Therapy vs Standard Therapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1058</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nausea 2nd 24 hours for Ketamine Therapy vs Standard Therapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay in Hospital</title>
        <description>Length of hospital stay measured in hours</description>
        <time_frame>Arrival at hospital until discharge from hospital, approximately 2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Therapy</title>
            <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Subjects received standard of care anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in Hospital</title>
          <description>Length of hospital stay measured in hours</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" spread="18.0"/>
                    <measurement group_id="O2" value="36.7" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Pain Control at Time of Hospital Discharge</title>
        <description>Self-reported questionnaire at the time of discharge from the hospital rating satisfaction of pain treatment while in the hospital using a scale of 0= extremely dissatisfied, 10 = extremely satisfied.</description>
        <time_frame>approximately 1-2 days post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Therapy</title>
            <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Subjects received standard of care anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Pain Control at Time of Hospital Discharge</title>
          <description>Self-reported questionnaire at the time of discharge from the hospital rating satisfaction of pain treatment while in the hospital using a scale of 0= extremely dissatisfied, 10 = extremely satisfied.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="0.9"/>
                    <measurement group_id="O2" value="8.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Pain Control at Postoperative Visit</title>
        <description>Self-reported questionnaire at the time of first post-operative visit with the surgeon, rating the worst amount of pain since being discharged from the hospital using a scale of 0= no pain, 10 = worst pain possible.</description>
        <time_frame>approximately 30 days post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Therapy</title>
            <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Subjects received standard of care anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Pain Control at Postoperative Visit</title>
          <description>Self-reported questionnaire at the time of first post-operative visit with the surgeon, rating the worst amount of pain since being discharged from the hospital using a scale of 0= no pain, 10 = worst pain possible.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.4"/>
                    <measurement group_id="O2" value="6.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected 30 days following surgery for each participant, over a study duration of approximately 48 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine Therapy</title>
          <description>Subjects received a ketamine bolus (0.3 mg/kg IV IBW) with induction; a ketamine infusion (0.2 mg/kg/hr IBW) was started after induction and terminated the next morning after surgical team rounds or at 24 hours</description>
        </group>
        <group group_id="E2">
          <title>Standard Therapy</title>
          <description>Subjects received standard of care anesthesia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew W. Gorlin</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>480-342-2446</phone>
      <email>Gorlin.Andrew@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

